Most men who think about STD testing are prompted by something specific. A condom that failed. A new partner. A niggling concern after a trip. The question feels urgent for a few days, then gets filed away when nothing obvious goes wrong.
The problem with that pattern is that most sexually transmitted diseases produce no symptoms at all — at least not initially, and often not ever. The Department of STI Control (DSC), Singapore’s national sexual health clinic, has consistently recorded chlamydia as the most commonly diagnosed STD in Singapore, with 2,719 new cases in 2018 alone.[1] Most of those cases involved no symptoms. The infection can persist, be passed to partners, and cause long-term complications without a single sign to prompt action.
The HIV picture in Singapore makes the same point more starkly. According to the Ministry of Health’s 2023 annual update, 51.2% of newly diagnosed HIV cases among Singapore residents were detected at late-stage infection — meaning the virus had been present, untested and untreated, for years.[2] Of those new cases, 95.2% were male.[2]
This is why the framing of “should I test?” matters. Testing after a scare is sensible. But for men who are sexually active, testing is better understood as something that happens on a schedule — calibrated to your situation — rather than something triggered only by a problem.
This article sets out when testing makes clinical sense, what a standard screen covers, and two infections — herpes and HPV — where the honest answer is more complicated than most clinics make clear.
Four situations where STD testing is clearly warranted
There is no universal answer to “how often should I test?” — it depends on your situation. But there are four specific scenarios where the clinical case for testing is clear.
After a specific exposure or concern
If you’ve had a sexual encounter that has left you with a specific concern — a condom failure, an unfamiliar partner, a partner who has since disclosed a positive result, or simply a feeling that something isn’t right — testing is appropriate.
The important caveat is timing. Different infections become detectable at different points after exposure, and testing too early can produce a falsely reassuring negative result. This is covered in detail in our companion article on the window period. As a general principle: if a specific exposure is your reason for testing, the consultation should include a discussion about when to test for each infection, not just whether to test.
Before stopping barrier contraception with a new partner
A baseline screen before removing condom use from a new relationship is straightforward clinical sense. Many bacterial STDs are asymptomatic in both partners, so neither person can rely on the absence of symptoms to determine current status. A full screen takes one appointment; most results return within a few working days.
When you have symptoms
Symptoms that should prompt testing include: penile discharge (any colour or consistency), pain or burning on urination, sores, blisters or ulcers in the genital area, rashes, unexplained groin lumps, testicular pain or swelling, or persistent flu-like illness following a potential exposure.
Two points worth noting. First, these symptoms are not specific — they can have other causes. Second, symptoms are neither necessary nor sufficient for deciding whether to test: most infected men have none, and symptoms when they do appear can resolve spontaneously without the underlying infection clearing. The absence of symptoms is not a reason to avoid testing; their presence is a reason to act promptly.
Periodically, if your situation calls for it
For men with multiple partners, men in non-monogamous relationships, or men on HIV PrEP, periodic testing on a regular schedule is a meaningful part of sexual health management, not a sign that something has gone wrong.
Both the Ministry of Health (MOH) and the Health Promotion Board (HPB) recommend HIV testing every three to six months for individuals engaging in high-risk sexual behaviour.[2] The same interval is a reasonable starting point for broader STD screening in men at higher risk. A 2026 retrospective cohort study of MSM patients at Singapore’s DSC Clinic (2018–2023), published in the Annals of the Academy of Medicine Singapore, confirmed that regular multi-site testing is the standard of care for this group.[3]
For men with one long-term partner after mutual confirmed testing, the calculation is different. Annual testing is a reasonable baseline for most sexually active men as a general health practice, even without a specific concern.
If you are unsure how often you should be testing given your situation, that question is worth putting to a doctor rather than working out from a general guideline.
What a standard STD screen covers — and why
A comprehensive STD screen typically covers chlamydia, gonorrhoea, syphilis, HIV, hepatitis B and hepatitis C. Each is included for a specific clinical reason.
Chlamydia and gonorrhoea
These are the two most commonly reported bacterial STDs in Singapore, as recorded in DSC surveillance data.[1] Both are frequently asymptomatic, particularly in men, and both are reliably detected by nucleic acid amplification testing (NAAT) from a urine sample. Both are treatable with antibiotics. The rationale for including both in routine screening is strong: testing changes management, treatment is effective, and leaving either untreated carries real long-term risks.
Syphilis
Syphilis is detected by blood serology. Its primary presentation — a painless sore, or chancre — is often overlooked or resolves spontaneously, which is why blood testing is necessary. According to CDC laboratory guidelines published in 2024, the incubation period for primary syphilis is 10–90 days, with an average of approximately three weeks.[4] Untreated, syphilis progresses through secondary and latent stages, and in a small proportion of cases to tertiary disease with serious cardiovascular and neurological consequences. It is fully treatable at early stages.
HIV
HIV is tested by a blood test. The Singapore context here is worth stating plainly: more than half of newly diagnosed HIV cases among Singapore residents in 2023 were already at late-stage infection at the time of diagnosis, according to MOH data.[2] Modern fourth-generation antigen/antibody combination tests are both highly sensitive and detect infection earlier than older tests. A negative result at 45 days post-exposure is considered conclusive by current BHIVA/BASHH guidelines.[5] HIV is not curable, but with antiretroviral therapy it is entirely manageable, and a person on effective treatment can have an undetectable viral load and a normal life expectancy. Knowing your status matters.
Hepatitis B and C
Both hepatitis B and C are blood-borne viruses transmissible through sexual contact, and both can cause chronic liver disease if untreated. Hepatitis B has a vaccine. Hepatitis C now has highly effective curative treatment. Both are included in a comprehensive screen because they are detectable, treatable, and asymptomatic in many people for years. Singapore has historically had a relatively high hepatitis B carrier rate compared to other developed countries, making it a locally relevant inclusion.[6]
A standard panel does not cover every possibility. If you have a specific concern about a particular exposure, the right tests may differ from the routine screen — a doctor can advise on what is relevant to your situation.
Herpes and HPV: why these are handled differently
Patients sometimes notice that a standard STD screen does not routinely include testing for herpes or HPV, and wonder why. This is not an oversight — it reflects a specific clinical rationale that is worth explaining clearly.
Herpes (HSV)
Genital herpes is caused by herpes simplex virus, usually type 2 (HSV-2), though HSV-1 is increasingly common at genital sites. It is highly prevalent globally, and the majority of people carrying the virus have no symptoms or do not recognise them.
The key clinical issue is that routine blood testing (serology) for HSV in asymptomatic people is not recommended by major clinical guideline bodies, including the US Preventive Services Task Force (USPSTF), the CDC, the American College of Obstetricians and Gynecologists, and UK National Guidelines. The USPSTF issued a formal D-grade recommendation — their strongest evidence against a test — against routine serologic HSV screening in asymptomatic adolescents and adults in 2023.[7]
The reasons are specific. HSV-2 IgG serology has a meaningful false-positive rate, particularly at borderline values between 1.1 and 3.0 on the standard assay.[8] A positive result in an asymptomatic person does not change clinical management: there is no curative therapy, and the decision to use suppressive antiviral treatment involves a nuanced risk-benefit calculation. The psychosocial consequences of a false positive diagnosis — anxiety, stigma, impact on relationships — are real and not trivial.
Testing for herpes is appropriate and clinically useful in specific circumstances: when there are symptoms (sores, blisters, ulcers), when a partner has a confirmed diagnosis, or when a lesion needs laboratory confirmation. In those situations, swab testing during an active outbreak is both sensitive and informative.
HPV
Human papillomavirus (HPV) is one of the most common sexually transmitted infections. Most infections clear spontaneously without causing any disease. Some HPV strains cause genital warts; a smaller group of high-risk strains are linked to cancers of the penis, anus and oropharynx in men.
Routine HPV screening is not recommended for men by the CDC or any major international guideline body,[9] and no licensed, validated HPV screening test exists for men in the way cervical screening exists for women. The reason is practical: there is no established screening programme for men, no anatomical site equivalent to the cervix for routine HPV testing, and no approved treatment that would change based on a positive test result in an asymptomatic man. A 2025 review in Frontiers in Cellular and Infection Microbiology confirmed the continued absence of uniform clinical guidelines for male HPV screening and the limited availability of validated testing methods.[10]
Management of HPV-related disease in men is based on clinical presentation: genital warts are treated when present, and men at higher risk of anal cancer (those living with HIV, or men who receive anal sex) may be offered specialist review. HPV vaccination — discussed separately in our Sexual Wellness & STD section — is the most meaningful preventive intervention available.
The reason we explain this rather than simply omitting herpes and HPV from the panel is that the question of why they are not routinely included is entirely reasonable. Good medicine involves explaining the reasoning, not just the checklist.
If something comes back positive
The anxiety that keeps men from testing is often not about the test itself. It is about what happens if the result is not what they hoped for.
For the bacterial infections — chlamydia, gonorrhoea, syphilis — treatment is a short course of antibiotics, often a single dose or a few days. Clearance is confirmed by follow-up testing. The clinical path is straightforward.
For viral infections, the picture is more individual. HIV is manageable, not curable — but people on effective antiretroviral therapy have a normal life expectancy, and an undetectable viral load eliminates the risk of sexual transmission. Herpes is manageable with suppressive antivirals. Hepatitis C now has a highly effective curative treatment. Hepatitis B has effective long-term management and a preventive vaccine.
Any positive result should be discussed with your doctor in person, not conveyed over a message or portal. Partner notification — which can feel like the hardest part — is something a good clinic will help you navigate, not leave you to manage alone.
The clinical consensus across all these conditions is the same: knowing is always better than not knowing. A result you are aware of can be acted on. One you defer finding out can cause harm quietly for years — a pattern Singapore’s own HIV data illustrates clearly.
If you are unsure whether your situation warrants testing — or which tests are appropriate — a short consultation with a doctor is more useful than a home test kit. The right screen depends on what you have been exposed to and when.
A note on what comes next
This article covers when testing is appropriate. A companion article covers the window period in detail — specifically, when to test after a specific exposure to get a result you can rely on. That question has a more nuanced answer than most online guides suggest, and depends on which infection you are concerned about and which test is being used. When you are ready to arrange testing, a first consultation with a sexual health doctor begins with a short history and risk discussion. The goal is to test for what is relevant to your situation, at the right time, with proper follow-up on any results that need it.
- Department of STI Control (DSC), Singapore. STI Surveillance data, 2016 and 2018. Published by the National Skin Centre. Available at: nsc.com.sg/dsc.
- Ministry of Health Singapore. Update on the HIV/AIDS Situation in Singapore 2023 (July 2024). moh.gov.sg.
- Lim IH, et al. No increased incidence of bacterial sexually transmitted infections with PrEP use among men who have sex with men in a clinic cohort. Ann Acad Med Singapore. 2026. doi: annals.edu.sg/prep-and-sti-incidence-in-msm.
- Centers for Disease Control and Prevention. CDC Laboratory Recommendations for Syphilis Testing, United States, 2024. MMWR Recomm Rep. 2024;73(1):1–32. PMC10849099.
- BHIVA/BASHH/BIA. Adult HIV Testing Guidelines 2020. British HIV Association; 2020. bhiva.org.
- National Population Health Survey, Ministry of Health Singapore. Hepatitis B seroprevalence data.
- US Preventive Services Task Force. Serologic Screening for Genital Herpes Infection: Reaffirmation Recommendation Statement. JAMA. 2023;329(6):502–507.
- Feng M, et al. Relationship Between HSV-1 Serostatus and HSV-2 IgG Confirmation Results Using an Inhibition Assay. J Clin Microbiol. 2025;63(1):e01190-24. PMC11723493.
- Centers for Disease Control and Prevention. HPV and Men — STD Facts. cdc.gov.
- Ren W, Jin Y, Shi L, et al. The necessity and challenges of human papillomavirus testing for men. Front Cell Infect Microbiol. 2025;15:1563499. PMC12256477.